Search

Cancer cells frequently up-regulate DNA replication and repair proteins such as the multifunctional DNA2 nuclease/helicase, counteracting DNA damage due to replication stress and promoting survival. Therefore, we hypothesized that blocking both DNA replication and repair by inhibiting the bifunctional DNA2 could be a potent strategy to sensitize cancer cells to stresses from radiation or chemotherapeutic agents. We show that homozygous deletion of DNA2 sensitizes cells to ionizing radiation and camptothecin (CPT). Using a virtual high throughput screen, we identify 4-hydroxy-8-nitroquinoline-3-carboxylic acid (C5) as an effective and selective inhibitor of DNA2. Mutagenesis and biochemical analysis define the C5 binding pocket at a DNA-binding motif that is shared by the nuclease and helicase activities, consistent with structural studies that suggest that DNA binding to the helicase domain is necessary for nuclease activity. C5 targets the known functions of DNA2 in vivo: C5 inhibits resection at stalled forks as well as reducing recombination. C5 is an even more potent inhibitor of restart of stalled DNA replication forks and over-resection of nascent DNA in cells defective in replication fork protection, including BRCA2 and BOD1L. C5 sensitizes cells to CPT and synergizes with PARP inhibitors., Highlights • C5 binds to the helicase domain of DNA2 and inhibits its nuclease, ATPase, and helicase activities. • C5 inhibits DNA end resection for DNA double strand break repair and restart of stalled replication forks. • C5 suppresses over-resection of nascent DNA in cells defective in fork protection. • C5 sensitizes cancer cells to chemotherapeutic agents. Most chemotherapeutics introduce DNA lesions that block DNA replication to kill cancer cells. Upregulation of DNA repair proteins in cancer cells is a major reason for human cancer to become resistant to chemotherapeutics. DNA repair proteins such as DNA2 nuclease/helicase have long been proposed as targets for sensitization of cancer cells to chemotherapy. We identify a selective DNA2 inhibitor (C5) and demonstrate that DNA2 inhibition by C5 suppresses cancer cells to rescue stalled replication forks. Consequently, it sensitizes cancer cells to replication fork stalling agents such as camptothecin. Thus, C5 is a promising lead compound for developing new anticancer drugs.